Other languages Aligos Therapeutics, Inc.

Equities

ALGS

US01626L1052

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-14 pm EDT			5-day change	1st Jan Change
0.5 ^USD	-1.59%		-7.42%	-24.70%

May. 22	Aligos Therapeutics, Inc. Announces Resignation of Jack Nielsen as Member of the Board of Directors	CI
May. 21	Aligos Therapeutics Announces the Completion of Enrollment in the ALG-055009 Phase 2A Herald Study for the Treatment of Mash	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Aligos Therapeutics, Inc. Announces Resignation of Jack Nielsen as Member of the Board of Directors	May. 22
Aligos Therapeutics Announces the Completion of Enrollment in the ALG-055009 Phase 2A Herald Study for the Treatment of Mash	May. 21
Aligos Therapeutics, Inc. Announces the Resignation of Matthew McClure as Chief Medical Officer	May. 15
Aligos Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 07
Aligos Therapeutics, Inc. Announces First Subjects Dosed in the Phase 2a HERALD Study of ALG-055009 in MASH Subjects	Apr. 03
Aligos Therapeutics Presents Positive Clinical Data at APASL 2024 from ALG-055009 and ALG-000184 Phase 1 Studies	Mar. 27
Aligos Therapeutics, Inc. Announces the Initiation of the Phase 2a HERald Study of ALG-055009 in MASH Subjects	Mar. 18
Aligos Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 12
Aligos Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Mar. 12
Aligos Therapeutics, Inc. Presents Positive Clinical Data at Hep-DART 2023 from Phase 1 Studies in HBV (ALG-000184) and NASH (ALG-055009)	Dec. 07
Aligos Therapeutics, Inc. Announces Executive Changes	Nov. 15
Aligos Therapeutics, Inc. Presents Clinical and Nonclinical Data at the AASLD Liver Meeting®? 2023	Nov. 13
Aligos Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 02
Aligos Therapeutics Insider Bought Shares Worth $6,004,149, According to a Recent SEC Filing	23-10-27
Aligos Says Investigational New Drug Application Application Cleared By US FDA for Thyroid Hormone Receptor Beta Agonist	23-09-21
Aligos Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-03
Aligos Therapeutics Presents Data from Its Liver Disease Programs At the European Association for the Study of the Liver Congress 2023	23-06-21
Sector Update: Health Care Stocks Edge Higher Premarket Monday	23-05-15
Top Premarket Gainers	23-05-15
Aligos Therapeutics to Collaborate with Xiamen Amoytop Biotech on Liver Disease Treatments; Aligos Shares Jump	23-05-15

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Aligos Therapeutics, Inc.

Equities

ALGS

US01626L1052

Other languages

Filters